Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells

 

 Buy Article Permissions and Reprints

Summary

TAFI (thrombin-activatable fibrinolysis inhibitor) is a carboxypeptidase zymogen originally identified in plasma. The TAFI pathway helps to regulate the balance between the coagulation and fibrinolytic cascades. Activated TAFI (TAFIa) can also inactivate certain pro-inflammatory mediators, suggesting that the TAFI pathway may also regulate communication between coagulation and inflammation. Expression in the liver is considered to be the source of plasma TAFI. TAFI has also been identified in platelets and CPB2 (the gene encoding TAFI) mRNA has been detected in megakaryocytic cell lines as well as in endothelial cells. We have undertaken a quantitative analysis of CPB2 mRNA and TAFI protein in extrahepatic cell types relevant to vascular disease. Using RT-PCR and quantitative RT-PCR, we detected CPB2 mRNA in the human megakaryoblastic cell lines MEG-01 and Dami, the human monocytoid cell line THP-1 as well as THP-1 cells differentiated into a macrophage-like phenotype, and in primary human umbilical vein and coronary artery endothelial cells. CPB2 mRNA abundance in MEG-01, Dami, and THP-1 cells was modulated by the state of differentiation of these cells. Using a recently developed TAFIa assay, we detected TAFI protein in the lysates of the human hepatocellular carcinoma cell line HepG2 as well as in MEG-01 and Dami cells and in the conditioned medium of HepG2 cells, differentiated Dami cells, and THP-1 macrophages. We have obtained clear evidence for extrahepatic expression of TAFI, which has clear implications for the physiological and pathophysiological functions of the TAFI pathway.

• References

• 1 Nesheim M. Thrombin and fibrinolysis. Chest 2003; 124: 33S-39S.
  CrossrefPubMedGoogle Scholar
• 2 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
  CrossrefPubMedGoogle Scholar
• 3 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
  CrossrefPubMedGoogle Scholar
• 4 Mao SS, Cooper CM, Wood T. et al. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-35052.
  CrossrefPubMedGoogle Scholar
• 5 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
  CrossrefPubMedGoogle Scholar
• 6 Eaton DL, Malloy BE, Tsai SP. et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
  PubMedGoogle Scholar
• 7 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-939.
  CrossrefPubMedGoogle Scholar
• 8 Hendriks D, Scharpé S, van Sande M. et al. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-285.
  PubMedGoogle Scholar
• 9 Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 13333-13339.
  CrossrefPubMedGoogle Scholar
• 10 Schneider M, Brufatto N, Neill E. et al. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004; 279: 13340-13345.
  CrossrefPubMedGoogle Scholar
• 11 Frère C, Morange PE, Saut N. et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94: 373-379.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
  PubMedGoogle Scholar
• 13 Meltzer ME, Lisman T, de Groot PG. et al. Venous thrombosis risk associated with plasma hypofibirnolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
  CrossrefPubMedGoogle Scholar
• 14 Eichinger S, Schönauer V, Weltermann A. et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-3776.
  CrossrefPubMedGoogle Scholar
• 15 Leebeek FW, Goor MP, Guimaraes AH. et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3: 2211-2218.
  CrossrefPubMedGoogle Scholar
• 16 Santamaría A, Oliver A, Borrell M. et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34: 2387-2391.
  CrossrefPubMedGoogle Scholar
• 17 Rooth E, Wallen H, Antovic A. et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coag Fibrinolysis 2007; 18: 365-370.
  CrossrefPubMedGoogle Scholar
• 18 Ladenvall C, Gils A, Jood K. et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27: 955-962.
  CrossrefPubMedGoogle Scholar
• 19 de Bruijen EL, Gils A, Guimarães AH. et al. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 2009; 7: 919-927.
  CrossrefPubMedGoogle Scholar
• 20 Trégouet DA, Schnabel R, Alessi MC. et al. Activated thrombin activatable fibrnolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the Athero Gene study. J Thromb Haemost 2009; 7: 49-57.
  CrossrefPubMedGoogle Scholar
• 21 Campbell WD, Lazoura E, Okada N. et al. Inactivation of C3a and C5a octapep-tides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-134.
  CrossrefPubMedGoogle Scholar
• 22 Hendriks D, Wang W, van Sande M. et al. Human serum carboxypeptidase U: a new kininase?. Agents Actions Suppl 1992; 38: 407-413.
  PubMedGoogle Scholar
• 23 Myles T, Nishimura T, Yun TH. et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
  CrossrefPubMedGoogle Scholar
• 24 Leung LL, Myles T, Nishimura T. et al. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45: 4080-4083.
  CrossrefPubMedGoogle Scholar
• 25 Du XY, Zabel BA, Myles T. et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem 2009; 284: 751-758.
  CrossrefPubMedGoogle Scholar
• 26 Van Thiel DH, George M, Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 2001; 85: 667-670.
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Boffa MB, Reid TS, Joo E. et al. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38: 6547-6558.
  CrossrefPubMedGoogle Scholar
• 28 Mosnier LO, Buijtenhuijs P, Marx PF. et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-4846.
  CrossrefPubMedGoogle Scholar
• 29 Hori Y, Gabazza EC, Yano Y. et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-665.
  CrossrefPubMedGoogle Scholar
• 30 Aubert H, Frère C, Aillaud MF. et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1: 791-797.
  CrossrefPubMedGoogle Scholar
• 31 Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499.
  CrossrefPubMedGoogle Scholar
• 32 Ogura M, Morishima Y, Ohno R. et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384-1392.
  PubMedGoogle Scholar
• 33 Greenberg SM, Rosenthal DS, Greeley TA. et al. Characterization of a new megakaryocytic cell line: the Dami cell. Blood 1988; 72: 1968-1977.
  PubMedGoogle Scholar
• 34 Tsuchiya S, Yamabe M, Yamaguchi Y. et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-176.
  CrossrefPubMedGoogle Scholar
• 35 Zhao SP, Deng P, Huang H. et al. Expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and its significance. 2005; Clinical Chemistry 51: 2170-2173.
  CrossrefPubMedGoogle Scholar
• 36 Maret D, Boffa MB, Brien DF. et al. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. J Thromb Haemost 2004; 2: 1969-1979.
  CrossrefPubMedGoogle Scholar
• 37 Boffa MB, Nesheim ME, Koschinsky ML. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001; 1: 59-74.
  CrossrefPubMedGoogle Scholar
• 38 Boffa MB, Wang W, Bajzar L. et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-2135.
  CrossrefPubMedGoogle Scholar
• 39 Gils A, Alessi MC, Brouwers E. et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-1127.
  CrossrefPubMedGoogle Scholar
• 40 Kim PY, Foley J, Hsu G. et al. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2008; 372: 32-40.
  CrossrefPubMedGoogle Scholar
• 41 Isakari Y, Sogo S, Ishida T. et al. Gene expression analysis during platelet-like particle production in phorbol myristate acetate-treated MEG-01 cells. Biol Pharm Bull 2009; 32: 354-358.
  CrossrefPubMedGoogle Scholar
• 42 Perez A, Thuillard JL, Bentzen CL. et al. Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. Cell Biol Toxicol 2003; 19: 95-105.
  CrossrefPubMedGoogle Scholar
• 43 Fugman DA, Witte DP, Jones CL. et al. In vitro establishment and characterization of a human megakaryoblastic cell line. Blood 1990; 75: 1252-1261.
  PubMedGoogle Scholar
• 44 Briquet-Laugier V, El Golli N, Nurden P. et al. Thrombopoietin-induced Dami cells as a model for alpha-granule biogenesis. Platelets 2004; 15: 341-344.
  CrossrefPubMedGoogle Scholar
• 45 Schadinger SL, Lin JHH, Garand M. et al. Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. J Thromb Haemost 2010; 8: 2523-2529.
  CrossrefPubMedGoogle Scholar
• 46 Auwerx J. The human leukemia cell line, THP-1: a multifecetted model for the study of monocyte-macrophage differentiation. Experentia 1991; 47: 22-31.
  CrossrefPubMedGoogle Scholar
• 47 te Velde EA, Wagenaar GT, Reijerkerk A. et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-2096.
  CrossrefPubMedGoogle Scholar
• 48 Swaisgood CM, Schmitt D, Eaton D. et al. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110: 1275-1282.
  CrossrefPubMedGoogle Scholar
• 49 Verbon A, Meijers JC, Spek CA. et al. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis 2003; 187: 55-61.
  CrossrefPubMedGoogle Scholar
• 50 Emonts M, de Bruijne EL, Guimarães AH. et al. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 2008; 6: 268-276.
  CrossrefPubMedGoogle Scholar
• 51 Bengtson SH, Sandén C, Mörgelin M. et al. Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system. J Innate Immun 2008; 1: 18-28.
  PubMedGoogle Scholar
• 52 Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
  CrossrefPubMedGoogle Scholar